Am Fam Physician. 2009 Mar 1;79(5) Online.
Background: Presenting smokers with evidence of early lung damage is believed to increase quit rates; however, a Cochrane review found insufficient evidence to support the use of personal biomarkers in smoking cessation strategies. Parkes and colleagues studied the impact of informing smokers of their "lung age" (age of the average person who has a forced expiratory volume [FEV1] equal to the smoker) on quit rates.
The Study: Smokers 35 years and older were recruited from five general practices in one county in England. Patients using oxygen and those with a history of tuberculosis, lung cancer, asbestosis, silicosis, bronchiectasis, or pneumonectomy were not eligible for the study. The baseline assessment included medical and smoking history, medication use, and standardized assessments of the impact of respiratory disease on daily life (the St. George's respiratory questionnaire) and of the smoker's readiness to change. Spirometry was completed on all participants to assess FEV1, forced vital capacity (FVC), and the FEV1/FVC ratio. The FEV1 results were used to estimate a lung age for each smoker.
More than 500 participants were randomly allocated to the intervention or control group. All participants were encouraged to quit smoking and were provided information on locally available smoking cessation services. Participants in the intervention group were also provided with verbal and illustrative information about their lung age and were counseled that quitting would slow the rate of deterioration in lung function. Persons in the control group only received numerical spirometry results. Spirometry was offered again after 12 months. The primary outcome was confirmed smoking cessation at 12 months. Self-reported quitting was confirmed by carbon monoxide breath testing and cotinine saliva levels. Secondary outcomes included daily cigarette use and new diagnoses of medical conditions.
Results: The control group (281 participants) included significantly more persons with a history of stroke than the intervention group (280 participants), but the groups did not differ significantly in any other variable. The average participant reported 33 pack-years of smoking, and 20 percent had significant comorbidities. Abnormal lung function was found in 23.5 percent of persons in the control group and 26.8 percent of persons in the intervention group.
Thirty-two persons from the control group and 31 from the intervention group did not return for follow-up. Assuming these participants continued to smoke, the verified quit rates were 6.4 percent in the control group and 13.6 percent in the intervention group. This difference is highly statistically significant. The estimated number needed to treat for the intervention to achieve one additional quitter was 14. In those who continued to smoke, the average daily cigarette use was significantly lower in the intervention group (11.7 compared with 13.7). The estimated cost of the intervention was $40 per patient processed or $556 per successful quitter.
Conclusion: The authors conclude that informing smokers of their lung age is associated with comparable quit rates to other strategies, such as counseling, nicotine replacement, or pharmacologic aids. The severity of lung damage on spirometry did not appear to be associated with the chances of quitting, but the study did not have sufficient power to establish any significant association.
Parkes G, et al. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. March 15, 2008;336(7664):598-600.
EDITOR'S NOTE: The authors of an accompanying editorial suggest that the method of providing information about lung function explains the positive outcome of this study compared with other studies using biomarkers in smoking cessation.1 They state that the crucial factors were the focus on the "lung age" concept and the use of highly personalized information and high-impact graphics, including diagrams of the projected rate of decline in lung function with and without continued smoking.
The intervention group quit rate of 13.6 percent at one year is comparable with the 14 to 16 percent reported with bupropion (Wellbutrin) and approaches the confidence intervals (CIs) reported in studies of varenicline (Chantix) 1 mg twice daily (quit rate of 21 to 22 percent; 95% CI, 17 to 26 percent).2 About 11 percent of the intervention group and 8 percent of the control group reported using a smoking cessation strategy (e.g., counseling, nicotine replacement, acupuncture, bupropion), but the article does not explore the contribution of these additional strategies to the quit rate. Nevertheless, allowing for differences in study design and other factors, providing feedback on lung age could be as effective and certainly less costly than other smoking cessation strategies.
A large practice-based randomized controlled trial based on this study would be really interesting, especially if it included an intervention group that was offered an additional strategy, as well as the controls and interventions described above. Despite all efforts, confirmed quit rates at one year remain far from good; therefore, new primary or adjunctive strategies are urgently needed. – A.D.W.
1. Bize R, Cornuz J. Incentives to quit smoking in primary care. BMJ. 2008;336(7664):567-568.
2. Physicians' Desk Reference 2007. 61st ed. Montvale, N.J.: Thomson PDR, 2007:2519.
Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions